Blood cancer is diagnosed through a series of tests that typically begins with routine blood work and, depending on results, progresses to bone marrow sampling, imaging, and genetic analysis. The process can take anywhere from a few days to several weeks, since each test builds on the last and some require specialized lab work. Understanding what happens at each stage can help you know what to expect if you or someone close to you is going through this.
It Usually Starts With a Blood Test
A complete blood count, or CBC, is the most common first step. This simple blood draw measures three key cell types: red blood cells, white blood cells, and platelets. For adults, typical white blood cell counts fall between 3.4 billion and 9.6 billion cells per liter. Red blood cell counts range from roughly 3.92 to 5.65 trillion cells per liter depending on sex, and platelet counts from about 135 billion to 371 billion per liter.
Counts that fall significantly above or below these ranges raise a flag. A very high white blood cell count can suggest leukemia, while unusually low red blood cells or platelets may point to cancer crowding out healthy cells in the bone marrow. An abnormal CBC alone doesn’t confirm blood cancer. Infections, nutritional deficiencies, and medications can all skew results. But when numbers are far enough outside the normal range, or when combined with symptoms like unexplained fatigue, frequent infections, easy bruising, or swollen lymph nodes, your doctor will order more targeted testing.
Physical Exam and Early Clues
Before or alongside blood work, a physical exam can reveal signs that point toward a blood cancer. Doctors check for enlarged lymph nodes in the neck, armpits, and groin. They also feel for an enlarged spleen, which sits under your left ribcage. A spleen wider than about 10 centimeters (roughly 4 inches) on imaging is generally considered enlarged, and in some blood cancers, particularly certain leukemias and lymphomas, it can grow large enough to extend into the lower abdomen.
These physical findings don’t diagnose cancer on their own, but they help determine which tests come next and how urgently they’re needed.
Bone Marrow Biopsy and Aspiration
For suspected leukemia and myeloma, bone marrow testing is the cornerstone of diagnosis. This procedure actually involves two samples taken during the same visit, usually from the back of the hip bone.
First comes the aspiration: a thin needle draws out a small amount of liquid marrow. This fluid sample lets pathologists examine individual cells under a microscope, checking their size, shape, and maturity. Then comes the biopsy itself, which uses a slightly larger needle to extract a tiny core of solid marrow tissue. This solid sample shows how cells are arranged within the marrow and how densely packed they are, information the liquid sample alone can’t provide.
The area is numbed with local anesthetic, and the procedure typically takes 15 to 30 minutes. Most people describe a deep pressure sensation and a brief, sharp ache when the marrow is drawn out. Results from a standard pathology review usually come back within about 10 days, though some labs are faster. If frozen sections are prepared for urgent cases, preliminary results can be available in as little as 15 to 20 minutes, with more detailed analysis to follow.
Lymph Node Biopsy for Lymphoma
When lymphoma is suspected, the diagnostic approach shifts from bone marrow to lymph node tissue. The gold standard is a surgical excision, where an entire lymph node is removed and sent to pathology. According to a large survey published through the French Lymphopath network, excisional biopsies provided a definitive lymphoma diagnosis 98.1% of the time, compared to 92.3% for core needle biopsies.
That gap matters. Core needle biopsies, which use a hollow needle to extract a thin cylinder of tissue, are less invasive and faster to perform. But they carry a higher risk of inconclusive or inaccurate results. When expert pathologists reviewed difficult cases, they could classify 93.3% of excisional samples but only 81.4% of core needle samples. For this reason, guidelines recommend surgical excision as the standard of care for lymphoma diagnosis, reserving needle biopsies for situations where surgery isn’t practical, such as deep internal nodes that are harder to reach.
Flow Cytometry: Identifying the Cancer Subtype
Once abnormal cells are found, the next question is: what kind of blood cancer is this? Flow cytometry answers that by tagging cells with fluorescent markers that attach to specific proteins on their surface. Each type of blood cell carries a distinct combination of surface proteins, almost like a fingerprint.
This technique is especially important for distinguishing between subtypes of leukemia and lymphoma that can look similar under a microscope but behave very differently. For example, two types of B-cell lymphoma, chronic lymphocytic leukemia and mantle cell lymphoma, both carry a protein called CD5 on their surface. But their other markers differ: CLL cells show weak levels of CD20 and strong levels of CD23, while mantle cell lymphoma cells show brighter CD20 and lack CD23. These distinctions directly affect treatment decisions.
Flow cytometry also separates mature cancers from immature ones. Immature blood cancers, like acute leukemias, express proteins such as TdT and CD34 that disappear as cells mature. Identifying this difference is critical because acute and chronic blood cancers require very different treatment approaches and have different prognoses.
Genetic and Chromosomal Testing
Many blood cancers are driven by specific genetic changes, and identifying them is now a routine part of diagnosis. Two key techniques are used here.
The first is a test called FISH (fluorescence in situ hybridization), which uses fluorescent probes to spot chromosomal rearrangements. The classic example is the Philadelphia chromosome, found in most cases of chronic myeloid leukemia. This abnormality occurs when pieces of chromosomes 9 and 22 swap places, creating a fused gene that drives uncontrolled cell growth. FISH can detect this translocation even when standard chromosome analysis misses it, including in cases that appear Philadelphia-negative under conventional methods.
Beyond diagnosis, FISH helps track how well treatment is working. It can detect whether the abnormal chromosomes are disappearing during therapy, signaling remission, or persisting, which may indicate the cancer is resistant. It’s also used to identify genetic changes that predict how aggressive a cancer is likely to be, helping doctors and patients plan accordingly.
The second technique, PCR (polymerase chain reaction), amplifies tiny amounts of DNA to detect genetic mutations with extreme sensitivity. It can find one cancer cell among hundreds of thousands of normal ones, making it valuable for catching very early disease or monitoring for relapse after treatment.
Imaging: PET and CT Scans
Imaging plays the biggest role in lymphoma, where doctors need to know how many areas of the body are involved. International guidelines now recommend PET-CT as the standard imaging tool for Hodgkin lymphoma staging, replacing CT scans alone. PET-CT combines two types of information: the CT portion shows the size and location of lymph nodes and organs, while the PET portion reveals metabolic activity, essentially highlighting areas where cells are consuming more energy than normal, a hallmark of active cancer.
During staging, doctors score each suspicious area based on how much metabolic activity it shows compared to reference points in the body, specifically the liver and the space between the lungs. Low activity (at or below the liver) is generally considered negative, while activity significantly above the liver suggests active disease. This scoring system, known as the Deauville scale, is also used after treatment starts to measure how well the cancer is responding.
For leukemia and myeloma, imaging is less central to initial diagnosis but may be used to check for bone damage, enlarged organs, or spread outside the blood and marrow.
How Long the Full Process Takes
The timeline varies depending on the type of blood cancer suspected and how many tests are needed. A CBC result can come back within a day. If it triggers further testing, a bone marrow biopsy or lymph node excision might be scheduled within days to a couple of weeks. Standard pathology reports take up to 10 days. Genetic testing and flow cytometry can add another one to two weeks on top of that.
In total, going from initial suspicion to a confirmed diagnosis with full subtyping and staging often takes two to four weeks. Acute leukemias tend to move faster because they require urgent treatment, and labs may prioritize those samples. Lymphomas and chronic leukemias, while still serious, sometimes allow a slightly longer diagnostic window. The wait can feel agonizing, but each test adds a layer of precision that directly shapes which treatment will be most effective.